Scope
The joint ASH, ISTH, NHF and WFH guidance combines diagnostic and management recommendations for von Willebrand disease. The official executive summaries cover risk-based testing, subtype confirmation, desmopressin safety, procedural haemostasis, menstrual bleeding and obstetric planning. Most treatment recommendations are conditional and supported by low- or very-low-certainty evidence, making individualized specialist planning central.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Match testing to the pretest probability
- For low-probability suspected VWD, use a validated bleeding-assessment tool to decide who needs specific blood testing. This strong recommendation is supported most clearly in adult women; testing includes VWF antigen, platelet-dependent VWF activity and factor VIII activity. [1]
- Do not let a bleeding score alone decide whether testing is needed in patients with intermediate or high VWD probability. The recommendation is conditional for haematology referrals and strong for high-risk patients such as those with an affected first-degree relative, including people without bleeding symptoms. [1]
- Prefer newer platelet-binding assays such as VWF:GPIbM or VWF:GPIbR over ristocetin-cofactor activity when available; this is conditional, with low-certainty evidence. Perform activity assays in a laboratory with appropriate expertise. [1]
Use phenotype, baseline measurements and subtype-specific tests
- For type 1 VWD, the panel recommends VWF below 0.30 IU/mL regardless of bleeding, or below 0.50 IU/mL with abnormal bleeding. Use the laboratory’s lower normal limit if below 0.50; test at baseline health because bleeding, trauma and pregnancy can raise VWF. [1][3]
- When previously confirmed type 1 VWD has normal VWF levels with ageing, the panel conditionally suggests reconsidering rather than simply removing the diagnosis. A rise in VWF has not been established to mean bleeding symptoms resolve; use shared decision making. [1]
- For suspected increased-clearance type 1C VWD, the panel suggests a desmopressin trial with blood sampling at 1 and 4 hours after infusion rather than relying on a VWF-propeptide/antigen ratio. [1]
- After an abnormal initial VWD screen, the panel suggests a platelet-dependent activity/antigen ratio below 0.7, rather than below 0.5, for type 2A, 2B or 2M assessment. For further subtype investigation, use either multimer analysis or collagen-binding/antigen ratio. [1]
- For suspected type 2A or 2B needing further testing, the panel suggests targeted genetic testing rather than low-dose ristocetin-induced platelet agglutination to diagnose type 2B. For suspected type 2N, use VWF–factor VIII binding or targeted genetic testing when available. [1]
Establish response and avoid predictable harm
- For patients in whom desmopressin is suitable, primarily type 1 VWD, with baseline VWF below 0.30 IU/mL, the panel suggests a trial and treatment based on its result. It suggests against using desmopressin in this group without trial results. [2][3]
- Adults with type 1 VWD and baseline VWF at least 0.30 IU/mL may be presumed responsive, although confirming response is preferable and checking levels after administration is reasonable. Do not use desmopressin alone for major surgery or procedures where small bleeds can injure a critical organ. [2]
- Desmopressin is contraindicated in type 3 VWD because it is ineffective and in type 2B because of thrombocytopenia risk. It is generally contraindicated with active cardiovascular disease, seizure disorders, age below 2 years or type 1C during surgery, and should be avoided with pre-eclampsia. [2][3]
- Desmopressin can cause water retention and hyponatraemia. Restrict oral free water, use normal saline if intravenous fluid replacement is needed, and teach the symptoms requiring prompt evaluation. Labour fluids and oxytocic drugs further increase this risk. [2]
Balance recurrent bleeding and cardiovascular indications
- For VWD with severe, frequent bleeding, the panel conditionally suggests long-term prophylaxis rather than none. Reassess bleeding symptoms and the continuing need periodically. [2][3]
- When cardiovascular disease requires antiplatelet or anticoagulant treatment, the panel suggests giving the necessary treatment rather than withholding it solely because of VWD. Reassess bleeding risk with the patient, haematology and cardiovascular teams; severe bleeding phenotypes may need VWF-concentrate prophylaxis. [2][3]
Individualize haemostatic support to procedure and subtype
- For patients with VWD undergoing major surgery, the panel suggests maintaining both VWF activity and factor VIII at least 0.50 IU/mL for at least 3 days, or longer as clinically indicated, rather than targeting factor VIII alone. Individualize targets and duration to the procedure, bleeding history and laboratory access. [2]
- For patients with VWD undergoing minor surgery or invasive procedures, the panel suggests adding tranexamic acid to desmopressin or concentrate used to raise VWF activity to at least 0.50 IU/mL, rather than raising VWF alone. Individualize the plan to avoid overtreatment of low-risk procedures. [2]
- For minor mucosal procedures in type 1 VWD with baseline activity above 0.30 IU/mL and a mild bleeding phenotype, the panel suggests tranexamic acid alone rather than raising VWF activity. This exception is specific to that mild subgroup. [2]
- Type 3 VWD requires VWF concentrate for a meaningful activity rise, and many type 2 patients also need concentrate. For higher thrombosis risk, consider avoiding prolonged high VWF/factor VIII levels combined with prolonged tranexamic acid; local haemostasis can complement dental procedural care. [2]
Treat heavy menstrual bleeding and its consequences
- For VWD-associated heavy menstrual bleeding without a wish to conceive, the panel suggests hormonal therapy or tranexamic acid over desmopressin. If conception is desired, it suggests tranexamic acid over desmopressin; combinations may be needed when initial control is inadequate. [2][3]
- Regularly assess and treat iron deficiency or anaemia in heavy menstrual bleeding. A bleeding disorder does not remove the need for standard gynaecological assessment for fibroids, polyps or other pathology, particularly when first-line treatment fails. [2]
Plan anaesthesia, delivery and postpartum support in advance
- When neuraxial anaesthesia is otherwise suitable in labour, the panel suggests a VWF activity target of 0.50–1.50 IU/mL rather than above 1.50. This does not determine anaesthetic suitability or postpartum-haemorrhage targets; plan jointly with anaesthesia, obstetrics and haematology. [2][3]
- In pregnancy with VWD, arrange third-trimester VWF and factor VIII assessment with a delivery plan. Maintain VWF activity above 0.50 IU/mL while an epidural is in place and for at least 6 hours after removal. Assess postpartum thrombosis risk and provide prophylaxis when needed. [2]
- The panel suggests postpartum tranexamic acid in type 1 VWD or low VWF, potentially also types 2 and 3. Its oral regimen is 25 mg/kg, typically 1,000–1,300 mg, three times daily for 10–14 days or longer if bleeding remains heavy; discuss breastfeeding safety and bleeding benefits. [2]
Limitations and use
- This summary follows the two official 2021-guideline executive summaries. It is not a complete diagnostic algorithm, factor-concentrate prescription, desmopressin challenge protocol or major-bleeding resuscitation plan.
- Targets and medicine choices require subtype confirmation, clinical bleeding history, contraindication assessment and laboratory monitoring. Procedure-specific duration and local product availability cannot be inferred from a threshold alone.
- Neuraxial targets apply only after anaesthetic suitability is established. They are not universal delivery or postpartum-haemorrhage targets, and the postpartum tranexamic-acid regimen does not replace management of an active obstetric emergency.
- This House summary is based on the linked focused or condensed recommendation sources; it does not represent the complete original publication.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Von Willebrand disease: diagnosis and management — reviewed source bundle part 1
Selected recommendation material consulted
- Von Willebrand disease: diagnosis and management — reviewed source bundle part 2
Selected recommendation material consulted
- Von Willebrand disease: diagnosis and management — reviewed source bundle part 3
Selected recommendation material consulted
Publication details
- Issuing organisation
- ASH / ISTH / NHF / WFH
- Resource type
- Clinical practice guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.